Zp.dk
Title
Zealand Pharma
Description
About Us
Zealand Pharma is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative peptide-based products that target indications (diseases and symptoms) of significant unmet clinical need and commercial potential. Zealand Pharma’s specialized know-how in peptide chemistry enables the generation of novel peptide molecules with unique therapeutic qualities. Further, to manage technical risks, the Company focuses on optimizing and developing well-understood peptides with known mechanisms.
Since commencing commercial operations in 1999, three of Zealand Pharma’s product candidates have advanced into Phase II clinical trials and one into pre-clinical evaluation expected to enter phase I clinical studies in 2006. As part of the Company’s operations, Zealand Pharma has formed clinical development partnerships with leading pharmaceutical companies Sanofi-Aventis and Wyeth.
Zealand Pharma’s proprietary “SIP” technology aims to optimize the therapeutic profile of peptides by enhancing a compound’s distribution and persistence of such molecules in the human body, thereby enhancing their efficacy. The “SIP” technology also has an additional advantage in that it can be applied to a broad range of active peptides.
Languages
English
Logos
